| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11886-017-0899-X |
| P8608 | Fatcat ID | release_akkmhi6xevbw3lfo3f57ieflb4 |
| P698 | PubMed publication ID | 28840572 |
| P2093 | author name string | Diana H Kim | |
| Howard J Eisen | |||
| Feng-Ju Chien | |||
| P2860 | cites work | Ivabradine: Role in the Chronic Heart Failure Armamentarium | Q38842736 |
| Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study | Q39174869 | ||
| Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. | Q39305717 | ||
| SR Ca(2+)-ATPase/phospholamban in cardiomyocyte function | Q41252655 | ||
| PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design | Q41927225 | ||
| The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group | Q42556789 | ||
| Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 | ||
| Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Q44588075 | ||
| Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial | Q44655145 | ||
| Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure | Q46556129 | ||
| The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial | Q48395213 | ||
| Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study | Q48795012 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q57491397 | ||
| Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF) | Q59192097 | ||
| The perindopril in elderly people with chronic heart failure (PEP-CHF) study | Q61716699 | ||
| The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial | Q74452235 | ||
| Urocortin: advancing the neurohumoral hypothesis of heart failure | Q81579715 | ||
| A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure | Q84132371 | ||
| Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy) | Q87428730 | ||
| Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection | Q26740185 | ||
| The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan | Q26747165 | ||
| Recent advances in treatment of heart failure | Q26766223 | ||
| Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 | ||
| Combination of isosorbide dinitrate and hydralazine in blacks with heart failure | Q28292266 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) | Q28378044 | ||
| Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Q29618529 | ||
| Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association | Q30238784 | ||
| Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study | Q33845755 | ||
| Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial | Q34044803 | ||
| A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure | Q34106793 | ||
| Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure | Q34195822 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 | ||
| Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial | Q34310960 | ||
| Spironolactone for heart failure with preserved ejection fraction | Q34414462 | ||
| Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure | Q34620874 | ||
| Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment | Q34664894 | ||
| Treatment of hypertension in patients 80 years of age or older | Q34766135 | ||
| Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial | Q34817043 | ||
| Irbesartan in patients with heart failure and preserved ejection fraction | Q34877640 | ||
| Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies | Q35203569 | ||
| Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial | Q37066497 | ||
| Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial | Q37094366 | ||
| A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease | Q37098407 | ||
| Pharmacotherapy of heart failure with preserved ejection fraction | Q38425861 | ||
| Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial | Q38455453 | ||
| Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure | Q38639973 | ||
| Contemporary Approaches to Patients with Heart Failure | Q38730081 | ||
| The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? | Q38740646 | ||
| Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? | Q38817871 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 94 | |
| P577 | publication date | 2017-08-24 | |
| P1433 | published in | Current cardiology reports | Q26842345 |
| P1476 | title | Pharmacologic Management for Heart Failure and Emerging Therapies | |
| P478 | volume | 19 |
| Q58802237 | Getting site-specific with actomyosin inhibitors |
| Q57071192 | Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy |
| Q101056742 | Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: A systematic review |
Search more.